NEAR Protocol tops daily and weekly gains in the crypto market, with a 54% surge this week.

The NEAR Protocol’s native token has demonstrated a remarkable performance in 2023. The value of NEAR has soared by over 175% this year, achieving a notable increase of 20% just today, reaching approximately $3.55. This surge has elevated the market capitalization of NEAR to about $3.5 billion.

The increasing adoption of the NEAR Protocol is evident through on-chain metrics. The count of active daily wallets on the network has seen a dramatic increase of 975%, from 93,000 to over a million, from Dec. 1 to Dec. 19. In parallel, the network’s total daily transactions have risen by 170% since Dec. 3.

$NEAR just getting started. Expecting feed to be full of NEAR narrative in the next few weeks. Already started.First meme I'm seeing – NEAR does everything TIA does but better and much more. TIA 12.6b FDVNEAR 3.5b FDV

— The Crypto Dog 📈 (@TheCryptoDog) December 21, 2023

You might also like: Argentina will accept Bitcoin for contractual agreements, new minister says

Analysts anticipate a surge in discussions and interest in the NEAR Protocol in the forthcoming weeks as it gains more visibility. Thanks to its lower, fully diluted valuation and arguably superior technology, NEAR is positioned for substantial growth, especially compared to rivals such as TIA.

$NEAR – Every VC capitulated and probably went back to working day jobs after last cycle, hated coin so people will be late. Not us, buying spot since 1.8.We sell back to them in 2024. https://t.co/eflYsxt8db pic.twitter.com/eRFaIKVWFm

— Astekz (@astekz) December 21, 2023

There’s also a narrative among analysts that retail investors have maintained their interest despite venture capitalists stepping back from NEAR during the cryptocurrency downturn. This trend suggests that when institutional investors re-engage with the cryptocurrency market in future cycles, these retail investors might be able to sell their holdings at significantly higher prices.

Read more: Terraform Labs and SEC agree on confidentiality terms as trial approaches